p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy
Keywords:
Endometrial carcinoma, p53, Estrogen receptor, Progesterone receptorAbstract
CONTEXT: Diagnostic staging is an important prognostic factor for endometrial adenocarcinoma. Apart from the histological type and histological grade, some markers seem to be associated with the stage and biological behavior of the disease. Among these are p53, estrogen and progesterone receptors. OBJECTIVE: The objectives of the present study were: to compare histological type and grading of endometrial carcinoma in curettage and hysterectomy samples; to assess expression of p53, estrogen and progesterone receptors in curettage specimens; and to correlate these data with morphology and staging of the disease in hysterectomy specimens. TYPE OF STUDY: Retrospective. SETTING: Department of Pathology, Faculdade de Ciências Médicas, Universidade Estadual de Campinas. SAMPLE: Histological diagnosis from 51 consecutive files. PROCEDURES: Immunohistochemical reactions for p53, estrogen and progesterone receptors via the avidinbiotin-peroxidase method in 51 curettage samples endometrial carcinoma were compared with the morphological data and disease stage in hysterectomy. Marker expression was correlated with histological type and grade and the final stage of the disease. RESULTS: According to the histological type: 44 cases (86%) were of endometrioid and 7 (14%) non-endometrioid carcinoma. p53 expression was observed in 16% of endometrioid and 71% of non-endometrioid cases (p < 0.05). Although estrogen expression was more evident in endometrioid (54%) than non-endometrioid cases (29%), this was not statistically significant. Progesterone receptor expression was significantly higher in endometrioid than non-endometrioid cases (70% vs. 14%, p < 0.05). According to the histological grade: Estrogen and progesterone receptors were expressed more frequently in grade I endometrioid carcinoma, while p53 was mainly reported in tumor grades II and III. According to final disease stage: p53 and estrogen expression in curettage specimens was not related to stage; progesterone receptors, however, were expressed significantly less in advanced disease. CONCLUSION: p53 was observed in the majority of nonendometrioid and in high-grade endometrioid carcinoma, but was not related to stage. Estrogen and progesterone receptors were mainly found in grade I endometrioid carcinoma. The markers studied in curettage were no more valuable for predicting the disease stage than classical histological criteria.
Downloads
References
Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarci- noma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996;62(2):278-81.
Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46(1):5-27.
Brasil. Ministério da Saúde, Instituto Nacional do Câncer/Inca, Coordenação de Programas de Controle do Câncer. [Coordi- nation Office for Cancer Control Programs]. Pró-câncer no Brasil: dados dos registros de base hospitalar. Rio de Janeiro: Pró-onco; 1993.
Pedro AO, Pinto-Neto AM, Costa-Paiva LHS, Borges MH, Lane E. A neoplasia maligna como causa de óbito feminino no Complexo Hospitalar da Unicamp: um aspecto de transição epidemiológica. Rev Bras Ginecol Obstet 1996;18(4):349-53.
Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ, editor. Blaustein’s pathology of the female genital tract. 4th ed. Berlin: Springer-Verlag; 1994. p.439-86.
Gompel C, Silverberg SG. The Corpus Uteri. In: Gompel C, Silverberg SG, editors. Pathology in Gynecology and Obstetrics. 4th ed. Philadelphia: JB Lippincott Company; 1994. p.163-283.
Hendrickson MR, Kempson RL. The Uterine Corpus. In: Stern- berg SS, Antonioli DA, Mills SE, Carter D, Oberman HA, edi- tors. Diagnostic Surgical Pathology. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1994. p.2091-193.
Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994;170(1 Pt 1):246-52.
Geisler JP, Wiemann MC, Zhou Z, Miller GA, Geisler HE. p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol 1996;61(2):245-8.
Burton JL, Stewart RL, Healtley MK, Royds JA, Wells M. p53 expression, p21 expression and the apoptotic index in endome- trial endometrial adenocarcinoma. Histopathology 1999;35(3):221-9.
Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15(1):10-7.
- Honda T, Kato H, Imamura T, et al. Involvement of p53 gene mutations in human endometrial carcinomas. Int J Cancer 1993;53(6):963-7.
Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Histological Typing of Female Genital Tract Tumours: in collaboration with Pathologists in 10 Countries. 2nd ed. Heibelberg: Springer-Verlag; 1994.
Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96(8):889-92.
Burton JL, Wells M. Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium. Histopathology 1998;33(4):297-303.
Ioffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 1998;29(10):1150-9.
Noumoff JS, Menzin A, Mikuta J, et al. The ability to evaluate prognostic variables on frozen section in hysterectomies per- formed for endometrial carcinoma. Gynecol Oncol 1991;42(3):202-8.
Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW. Immunohistochemical profile of endometrial ad- enocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000;13(4):379-88.
Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000;76(3):287-90.
Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The fre- quency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrial and serous carcinoma evidence of distinct molecular genetic pathway. Cancer 2000;88(4):814-24.
Fernando SSE, Wu X, Perera LS. p53 Overexpression and Ster- oid Hormone Receptor Status in Endometrial Carcinoma. Int J Surg Pathol 2000;8(3):213-22.
Hamel NW, Sebo TJ, Wilson TO, et al. Prognostic value of p53 and proliferating cell nuclear antigen expression in endome- trial carcinoma. Gynecol Oncol 1996;62(2):192-8.
Ito K, Watanabe K, Nasim S, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994;54(17):4667-70.
Taskin M, Lallas TA, Barber HR, Shevchuk MM. bcl-2 and p53 in endometrial adenocarcinoma. Mod Pathol 1997;10(7):728-34.
Ozsaran AA Tüker S, Dikmen Y, et al. p53 staining as a prog- nostic indicator in endometrial carcinoma. Eur J Gynaecol Oncol 1999;20(2):156-9.
Elhafey AS, Papadimitriou JC, El-Hakim MS, et al. Compu- terized image analysis of p53 and proliferating cell nuclear an- tigen expression in benign, hyperplastic, and malignant en- dometrium. Arch Pathol Lab Med 2001;125(7):872-9.
Ambros RA, Vigna PA, Figge J, et al. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer 1994;73(6):1686-92.
Rose PG. Endometrial carcinoma. N Engl J Med 1996;335(9):640-9.
